ERBB2 and breast cancer: In conclusion, after the recurrence and metastasis of breast cancer, the expressions of ER, PR, HER2, and Ki-67 may be inconsistent between the primary and metastatic lesions, which is significant for the formulation of follow-up treatment plans and the evaluation of prognosis.